FDA, DOJ Take Enforcement Action Against Defiant 503B Compounder

FDA announced Thursday (March 1) that it is working with the Department of Justice to block a registered 503B compounder from “manufacturing, processing, packing, labeling, holding and/or distributing” its product after the company disobeyed FDA's wishes and continued compounding after it had to recall all of its sterile products in July 2017. “Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs...